386 High-dose chemotherapy with stem cell support in high-risk primary breast cancer. An analysis of the effect on overall survival the Danish experience from a comparison study

2003 ◽  
Vol 1 (5) ◽  
pp. S118
Author(s):  
T. Palshof ◽  
S. Werner Hansen ◽  
C. rose ◽  
S. Møller ◽  
P. Hokland ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Overall Survival ◽  
Stem Cell ◽  
High Risk ◽  
High Dose Chemotherapy ◽  
High Dose ◽  
Comparison Study ◽  
Stem Cell Support ◽  
Danish Experience ◽  
Cell Support

scholarly journals Adjuvant High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Support for High-Risk Primary Breast Cancer: Results from the Italian National Registry

2014 ◽  
Vol 20 (4) ◽  
pp. 501-506 ◽  
Author(s):  
Paolo Pedrazzoli ◽  
Giovanni Martinelli ◽  
Alessandro Massimo Gianni ◽  
Gian Antonio Da Prada ◽  
Alberto Ballestrero ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Stem Cell ◽  
High Risk ◽  
Primary Breast Cancer ◽  
High Dose Chemotherapy ◽  
National Registry ◽  
High Dose ◽  
Hematopoietic Stem ◽  
Stem Cell Support ◽  
Cell Support

scholarly journals High-Dose Chemotherapy With Autologous Stem-Cell Support As Adjuvant Therapy in Breast Cancer: Overview of 15 Randomized Trials

2011 ◽  
Vol 29 (24) ◽  
pp. 3214-3223 ◽  
Author(s):  
Donald A. Berry ◽  
Naoto T. Ueno ◽  
Marcella M. Johnson ◽  
Xiudong Lei ◽  
Jean Caputo ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Overall Survival ◽  
Stem Cell ◽  
Randomized Trials ◽  
High Dose Chemotherapy ◽  
High Dose ◽  
Relapse Free Survival ◽  
Free Survival ◽  
Stem Cell Support ◽  
Cell Support

Purpose Adjuvant high-dose chemotherapy (HDC) with autologous hematopoietic stem-cell transplantation (AHST) for high-risk primary breast cancer has not been shown to prolong survival. Individual trials have had limited power to show overall benefit or benefits within subsets. Methods We assembled individual patient data from 15 randomized trials that compared HDC versus control therapy without stem-cell support. Prospectively defined primary end points were relapse-free survival (RFS) and overall survival (OS). We compared the effect of HDC versus control by using log-rank tests and proportional hazards regression, and we adjusted for clinically relevant covariates. Subset analyses were by age, number of positive lymph nodes, tumor size, histology, hormone receptor (HmR) status, and human epidermal growth factor receptor 2 (HER2) status. Results Of 6,210 total patients (n = 3,118, HDC; n = 3,092 control), the median age was 46 years; 69% were premenopausal, 29% were postmenopausal, and 2% were unknown menopausal status; 49.5% were HmR positive; 33.5% were HmR negative, and 17% were unknown HmR status. The median follow-up was 6 years. After analysis was adjusted for covariates, HDC was found to prolong relapse-free survival (RFS; hazard ratio [HR], 0.87; 95% CI, 0.81 to 0.93; P < .001) but not overall survival (OS; HR, 0.94; 95% CI, 0.87 to 1.02; P = .13). For OS, no covariates had statistically significant interactions with treatment effect, and no subsets evinced a significant effect of HDC. Younger patients had a significantly better RFS on HDC than did older patients. Conclusion Adjuvant HDC with AHST prolonged RFS in high-risk primary breast cancer compared with control, but this did not translate into a significant OS benefit. Whether HDC benefits patients in the context of targeted therapies is unknown.

High-dose chemotherapy and stem-cell support in breast cancer

The Lancet ◽  
1998 ◽  
Vol 352 (9135) ◽  
pp. 1220
Author(s):  
Paolo Pedrazzoli ◽  
Gian Antonio Da Prada ◽  
Gioacchino Robustelli della Cuna
Keyword(s):  
Breast Cancer ◽  
Stem Cell ◽  
High Dose Chemotherapy ◽  
High Dose ◽  
Stem Cell Support ◽  
Cell Support

scholarly journals High dose chemotherapy with autologous hematopoietic stem cell support for solid tumors other than breast cancer in adults

2006 ◽  
Vol 17 (10) ◽  
pp. 1479-1488 ◽  
Author(s):  
P. Pedrazzoli ◽  
J.A. Ledermann ◽  
J.-P. Lotz ◽  
S. Leyvraz ◽  
M. Aglietta ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Stem Cell ◽  
Solid Tumors ◽  
Hematopoietic Stem Cell ◽  
High Dose Chemotherapy ◽  
High Dose ◽  
Hematopoietic Stem ◽  
Stem Cell Support ◽  
Cell Support

Randomized trial of high-dose chemotherapy and autologous hematopoietic stem cell support for high-risk primary breast carcinoma

Cancer ◽  
2006 ◽  
Vol 106 (11) ◽  
pp. 2327-2336 ◽  
Author(s):  
Emer O. Hanrahan ◽  
Kristine Broglio ◽  
Deborah Frye ◽  
Aman U. Buzdar ◽  
Richard L. Theriault ◽  
...  
Keyword(s):  
Stem Cell ◽  
High Risk ◽  
Breast Carcinoma ◽  
Randomized Trial ◽  
High Dose Chemotherapy ◽  
High Dose ◽  
Primary Breast Carcinoma ◽  
Hematopoietic Stem ◽  
Stem Cell Support ◽  
Cell Support

High-dose chemotherapy with autologous stem cell support in patients with breast cancer

1998 ◽  
Vol 24 (4) ◽  
pp. 249-263 ◽  
Author(s):  
Z.U. Rahman ◽  
G.N. Hortobagyi ◽  
A.U. Buzdar ◽  
R. Champlin
Keyword(s):  
Breast Cancer ◽  
Stem Cell ◽  
High Dose Chemotherapy ◽  
High Dose ◽  
Stem Cell Support ◽  
Cell Support
Sign in / Sign up

Export Citation Format

Share Document